Holen Sie sich die Stockscreener-App
2.11
0.96%
0.02
Handel nachbörslich:
2.12
0.01
+0.47%
Schlusskurs vom Vortag:
$2.09
Offen:
$2.06
24-Stunden-Volumen:
300.00K
Relative Volume:
0.27
Marktkapitalisierung:
$382.07M
Einnahmen:
$109.16M
Nettoeinkommen (Verlust:
$-107.78M
KGV:
-1.9073
EPS:
-1.1063
Netto-Cashflow:
$-95.45M
1W Leistung:
+4.20%
1M Leistung:
+4.98%
6M Leistung:
-13.17%
1J Leistung:
+340.69%
1-Tages-Spanne:
$2.06
$2.15
1-Wochen-Bereich:
$1.97
$2.15
52-Wochen-Spanne:
$0.435
$3.04
Century Therapeutics Inc Stock (IPSC) Company Profile
Firmenname
Century Therapeutics Inc
Sektor
Branche
Telefon
215-981-4000
Adresse
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Compare IPSC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
2.11 | 365.77M | 109.16M | -107.78M | -95.45M | -1.1063 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | TD Cowen | Buy |
| 2024-08-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-10-31 | Eingeleitet | Guggenheim | Buy |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-05-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-12 | Eingeleitet | William Blair | Mkt Perform |
| 2021-07-13 | Eingeleitet | BofA Securities | Buy |
| 2021-07-13 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-13 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Century Therapeutics Inc Aktie (IPSC) Neueste Nachrichten
Century (IPSC) Earnings Reading: EPS Beats Its Estimate at the Close; Share Move: The Stock Records a 4.27% Decrease in Latest TradingGuidance vs Actual - vinanet.vn
Century Targets FDA Filing for Diabetes Cell Therapy - MyChesCo
Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction - Kalkine Media
Century Therapeutics (IPSC) CEO stock withheld for taxes - Stock Titan
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings - MarketBeat
IPSC Q1 2026 Earnings: Narrower-Than-Expected Loss Yields 31.76% EPS SurpriseMid-Term Outlook - vinanet.vn
TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating - Moomoo
Century Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Century Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Century Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings Results - MarketBeat
Century Therapeutics Announces Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Century Therapeutics Inc For: 12 August - Investing.com India
Century Therapeutics Reports Q2 Results, Pipeline Advancements - TipRanks
Form 8K Century Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Century Therapeutics posts $34.6 million Q2 loss as cash runway reaches 2029 - Quiver Quantitative
Century Therapeutics 2Q 2026: Revenue $0 EPS $(0.17) — 10-Q Summary - TradingView
Century Therapeutics Q2 net loss misses estimates on lease termination loss - TradingView
Century Therapeutics (IPSC) books $34.6M loss but holds $197M cash - Stock Titan
FDA and Century Align on Type 1 Diabetes Therapy Trial Plan - Stock Titan
We Think Century Therapeutics (NASDAQ:IPSC) Needs To Drive Business Growth Carefully - Moomoo
Century Therapeutics (IPSC) Projected to Announce Earnings on Thursday - MarketBeat
Century Therapeutics (IPSC) SVP has automatic share sale to cover RSU taxes - Stock Titan
Seven Fleet Capital Management LP Takes Position in Century Therapeutics, Inc. $IPSC - MarketBeat
DV Trading LLC Makes New Investment in Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Century Therapeutics Inc (IPSC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Century Therapeutics Inc (IPSC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Commodore Capital LP Purchases New Position in Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Inc (IPSC) Cash Flow - TradingKey
IPSC|Century Therapeutics Inc|Price:2.110|Chg%:-0.060 - TradingKey
Century Therapeutics Inc (IPSC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Century Therapeutics Inc (IPSC) Institutional Confidence - TradingKey
Century Therapeutics, Inc. Revenue Breakdown – NASDAQ:IPSC - TradingView
Spruce Street Capital LP Acquires 2,637,522 Shares of Century Therapeutics, Inc. $IPSC - MarketBeat
Century Therapeutics Q1 2026 Earnings: Narrower Loss Than Expected, But Stock FadesEPS Surprise History - Vinanet
IPSC stock trades steadily as Century Therapeutics updates its pipeline and cash runway - Ad-hoc-news.de
IPSC stock trades around recent lows as Century Therapeutics weighs pipeline and cash burn - Ad-hoc-news.de
Century Therapeutics (IPSC) Posts Modest Gain as Stock Holds Above Key Support LevelHigh Yield Stocks - vinanet.vn
Century Therapeutics (IPSC) Dips 2.7% as Shares Near Key Support ZoneDividend Stock Picks - dars.gov.et
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses - Yahoo Finance
Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential - Seeking Alpha
Century Therapeutics abstracts accepted for diabetes conferences - Investing.com
Century Therapeutics abstracts accepted for diabetes conferences By Investing.com - Investing.com South Africa
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026 - Investing News Network
Century Therapeutics (IPSC) Q1 2026 Earnings: Narrower Loss Surprises, Shares ClimbEarnings Growth Analysis - dars.gov.et
Frontier tech research, news & data - MLQ.ai
IPSC Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEstimate Dispersion - dars.gov.et
IPSCCentury Therapeutics Inc Short Interest - Finviz
Finanzdaten der Century Therapeutics Inc-Aktie (IPSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):